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Abstract: 
 
Objective: To evaluate the efficacy and safety of long duration DAPT (L-DAPT) compared to 
short duration DAPT (S-DAPT) after drug-eluting stent (DES) implantation.  
Methods: We searched Medline, Embase, and Cochrane Central Register of Controlled Trials 
(CENTRAL) to identify randomized controlled trials (RCTs) assessing the clinical impact of L-
DAPT versus S-DAPT after DES. Efficacy endpoints were all-cause mortality, cardiac mortality, 
myocardial infarction (MI), stent thrombosis (ST), and target vessel revascularization (TVR). 
Safety endpoints were TIMI major bleeding and stroke. Event rates were compared using a 
random effects model.  
Results: We identified eleven RCTs in which 33, 520 patients were randomized to S-DAPT 
(N=16, 687) and L-DAPT (n=16,833), respectively. Compared with L-DAPT, S-DAPT was 
associated with higher rate of MI and lower rate of TIMI major bleeding [1.40 (1.08, 1.81), and 
0.60 (0.41, 0.89), respectively], without any significant differences in the rate of all cause 
mortality, cardiac mortality, ST, TVR and stroke [0.88 (0.75, 1.04), 0.98 (0.79, 1.22), 1.54 (0.95, 
2.50), 0.99 (0.73, 1.34), and 1.01 (0.78, 1.32), respectively].  
Conclusion: Our results showed that compared with L-DAPT, S-DAPT was associated with 
higher rate of MI and lower rate of major bleeding without any significant difference in the rates 
of all cause mortality, cardiac mortality, ST, TVR, and stroke.  
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Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended to reduce 
incidence of ischemic events, including stent thrombosis (ST), an uncommon but life-threatening 
complication after drug eluting stenting (DES) implantation [1, 2]. However, optimal duration of 
DAPT after DES implantation remains debatable. Several randomized control trials (RCTs) 
directly comparing outcomes with short (S) (3-6 months) versus longer (L) (12-30 months) 
duration of DAPT have reported conflicting results [3-13]. Previous meta-analyses of RCTs 
comparing S-DAPT versus L-DAPT have shown inconsistent results [14-17]. Furthermore, 
results of most recent RCT comparing L-DAPT and S-DAPT- Optimal Duration of Dual 
Antiplatelet Therapy After Drug-eluting Stent Implantation (OPTIDUAL)- showed non 
superiority of L-DAPT (48 months) over standard (12 months) DAPT, after extended median 
follow up of 33 months [13]. However, the power of the OPTIDUAL was low as this study was 
prematurely terminated due to slow enrollment [13]. In this context, we conducted this updated 
meta-analysis of RCTs to investigate cumulative evidence for efficacy and safety of S-DAPT 
versus L-DAPT strategy after DES implantation.  
 
Methods: 
 
We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analyses) statement for reporting systematic reviews and meta-analyses of RCTs for the protocol 
of our meta-analysis [18]. 
 
We systematically searched PubMed, CINAHL, Cochran CENTRAL, Embase, Scopus and Web 
of Science databases for randomized clinical trials comparing different durations of DAPT after 
DES implantation. Pertinent trials were also searched in clinicaltrials.gov and in the proceedings 
of major international cardiology meetings (ACC, AHA, ESC, The Society for Cardiac 
Angiography and Interventions). DAPT was defined as aspirin plus a P2Y12 receptor inhibitor, 
after coronary DES implantation. S-DAPT and L-DAPT were defined as duration of DAPT after 
DES implantation </=12months and >12months, respectively. All relevant combinations of 
following keywords  “aspirin”, “P2Y12 receptor inhibitor “, “clopidogrel”, “Plavix”, 
“prasugrel”, “Effient”, “ticagrelor”, “Brilinta”, “thienopyridine”, “dual antiplatelet therapy”, 
“DAPT”, “drug eluting stents”, “DES”, “death”, “mortality”, “survival”, “cardiac mortality”, 
“stent thrombosis”, “Global Utilization Of Streptokinase And Tpa For Occluded Arteries 
(GUSTO) bleeding”, stroke, myocardial infarction, “randomized controlled trial”, “random”, 
“random allocation”, “double-blind”, and “single-blind” were included for database search. We 
manually searched references of identified studies. The search period took place from 1 January 
2002 to November 30, 2016. No language restrictions were applied. The corresponding authors 
of the relevant studies were queried for required quantitative details not in the published 
manuscripts. 
 
Two reviewers (AS, AG) independently screened the titles and abstracts for relevance. The 
manuscripts of selected titles/abstracts were reviewed for inclusion or exclusion using the above 
mentioned selection criteria. Two reviewers (AS, AG) independently determined the articles to 
be included and excluded, and data from the relevant articles were extracted using pre-defined 
extraction forms.  Any disagreements in data extraction were discussed until consensus was 
reached. Baseline patients characteristics and following data was extracted from selected studies 
at the end of follow up period: all-cause mortality, cardiac mortality, myocardial infarction (MI), 
ST, target vessel revascularization (TVR), major bleeding and stroke. 
 
The statistical analysis was performed according to the recommendations from the Cochrane 
Collaboration using Review Manager Version 5.1 (The Nordic Cochrane Center, The Cochrane 
Collaboration, 2008, Copenhagen) was used. A random-effects model with inverse variance 
weighting was used to calculate odds ratio (OR) and 95% confidence interval, associated with S-
DAPT versus L-DAPT for above end points. Forest plot was used to observe the overall effect of 
studies. Heterogeneity between studies was assessed using Cochrane’s Q test and I2 statistic, 
which denotes the percentage of total variation across studies that is a result of heterogeneity 
rather than chance. Heterogeneity was considered significant if the p value was less than 0.05. 
Publication bias was assessed by Begg’s test and Egger’s regression test.  
 
 
Results: 
 
 2692 publications were found at initial search and after abstract and manuscript evaluation 
eleven studies are selected for final analysis (Figure 1) [3-13]. In selected eleven RCTs, 33, 520 
patients were randomized to S-DAPT (N=16, 687) and L-DAPT (n=16,833), respectively. Mean 
follow up period in studies included in our analysis varies from 9 months to 33 months after 
completion of L-DAPT. Use of second generation DES varies from 36% to 100%.  
 
Clinical outcomes with S-DAPT as compared to L-DAPT are summarized in Table 1 and Figure 
2-8. Compared with L-DAPT, S-DAPT was associated with higher rate of MI [Odds Ratio (OR) 
1.40, 95% Confidence Interval (CI) (1.08, 1.81);Figure 2] and a lower rate of TIMI major 
bleeding [OR 0.60, 95% CI (0.41, 0.89);Figure 3]. However, there were no significant 
differences in the rate of all cause mortality, cardiac mortality, ST, TVR and stroke [OR 0.88 
95% CI (0.75, 1.04),Figure 4); OR 0.98, 95% CI (0.79, 1.22,Figure 5); OR 1.59, 95% CI (0.98, 
2.60,Figure 6); OR 0.99, 95% CI (0.73, 1.34,Figure 7); and OR 1.01, 95% CI (0.78, 1.32,Figure 
8); respectively] with S-DAPT as compared to L-DAPT. 
 
Discussion: 
 
The principal finding of the current meta-analysis, including over 33, 000 patients pooled 
from 11 RCTs evaluating various duration of DAPT is that S-DAPT was associated with 
significant reduction in the rate of TIMI major bleeding, which came at the cost of increased 
rates of MI and a trend towards an increase in ST. However, these differences did not 
translate into any significant differences in the rates of all-cause or cardiac mortality after 
percutaneous coronary intervention  (PCI) with placement of DES.  
 
Overall, our results are consistent with previous reports demonstrating reduction in MI and a 
trend towards reduction in ST with L-DAPT. There was a significant reduction in MI and ST 
in the L-DAPT arm of the DAPT study [9], and a trend towards decreased ST and MI in the 
EXCELLENT trial [4]. The reduction in MI did not translate into benefit in terms of CV 
mortality in our analysis. One of the potential explanations for this observation could be a 
change in MI definition over years [19], and thus inclusion of minor non-significant events, 
or improved survival after MI due to advances in treatments [20].  
 
Importantly, we did not observe the increased signal of all-cause mortality seen in the DAPT 
trial [9] or in a previous meta-analysis [21]. Increased all-cause mortality has been partly 
attributed to the observed higher risk of major bleeding with prolonged use of DAPT [9]. 
This finding is supported by a large observational study showing increased mortality risk 
with bleeding events after PCI [22]. However, a recent sub-analysis of the mechanisms of 
death occurring within the DAPT study found that the increase in all-cause mortality rates 
among the continued DAPT arm was driven entirely by an increase in non-CVdeaths, of 
which bleeding accounted for only a small portion of the of the observed difference in 
mortality (0.3% vs 0.2% continued DAPT vs aspirin alone, respectively). Rather, the 
difference was primarily attributed to cancer-related deaths without clinical evidence of 
bleeding (0.6% vs 0.3% DAPT vs aspirin alone, respectively) [23]. These unexpected 
findings raise concern about the use of L-DAPT among patient with advanced cancers.   
 
In the view of above findings, several points are worth mentioning. First, a major drawback 
in interpretation of clinical evidence so far has been adoption of ‘one size fits all policy’. 
Effect of DAPT after PCI with DES could be specifically related to clinical presentation, eg. 
acute coronary syndrome vs stable ischemic heart disease, or stent-type (1
st
 vs 2
nd
 
generation). Patients presenting with acute coronary events may have more persistent platelet 
activation and thus have more favorable ischemic-bleeding balance with prolonged DAPT 
[24]. This assumption is supported by a recent meta-analysis by Udell et al showing 
reduction in major adverse cardiovascular events (including cardiovascular mortality) with 
extended DAPT in patients with history of MI [25]. Similarly, there was no significant 
reduction in MACE in the L-APT arm of DAPT trial among patients who received 
everolimus eluting stents [9].  
 
Use of more potent P2Y12 inhibitors (prasugrel and ticagrelor) as compared to clopidogrel 
results in decreased ischemic risk and increased bleeding. In PLATO, treatment with 
ticagrelor 90 mg twice daily, compared with clopidogrel 75 mg once daily, for patients with 
ACS resulted in fewer ischemic complications and ST (9.8% vs. 11.7%, HR 0.84, 95% CI 
0.77–0.92) but more frequent bleeding (non-CABG related) at 12 months (4.5% vs. 3.8%, p 
= 0.03) [26]. In PEGASUS-TIMI 54, patients randomized 1 to 3 years after MI with 
additional high risk features to either DAPT (with ticagrelor 60 mg or 90 mg twice daily) or 
continued aspirin monotherapy resulted in a 1.2% to 1.3% absolute reduction in the primary 
composite endpoint of cardiovascular death, MI, or stroke and a 1.2% to 1.5% absolute 
increase in major bleeding, with no excess in fatal bleeding or intracranial hemorrhage [27]. 
In TRITON-TIMI 38, treatment with prasugrel 10 mg daily, compared with clopidogrel 75 
mg daily, among patients with ACS undergoing planned PCI, resulted in fewer ischemic 
complications and ST (9.9% vs. 12.1%, HR 0.81, 95% CI 0.73-0.90) but more frequent 
bleeding, including life-threatening and fatal bleeding (2.4% vs. 1.8%, HR 1.32 95% CI, 
1.03-1.68). Due to significantly higher rates of bleeding (as compared with clopidogrel), 
there was no net benefit of prasugrel therapy in those ≥75 years of age and those <60 kg, and 
there was net harm (including increased risk of intracranial hemorrhage) in those with prior 
stroke or transient ischemic attack (TIA) [28]. Thus, the current guidelines support the 
preferential use of ticagrelor over clopidogrel in patients with ACS after coronary stent 
implantation or medical therapy alone for maintenance P2Y12 inhibitor therapy (Class IIa) 
and prasugrel over clopidogrel after coronary stent implantation among those not at high risk 
for bleeding complications and who do not have a history of stroke or TIA (Class IIa) [29]. 
 
With respect to duration of DAPT, previous practice guidelines recommended treatment with 
P2Y12 receptor antagonists for 12 months after ACS irrespective of the revascularization 
strategy and 12 months in the non-ACS setting among patients who are not at high risk for 
bleeding (old nstmei/stemi acc/aha guidelines) [30-31]. The recently published 2016 
ACC/AHA Guideline Focused Update on the Duration of Dual Antiplatelet therapy in 
patients with Coronary Artery Disease updated these recommendations giving a class IIb 
recommendation for longer duration of DAPT beyond 12months with clopidogrel, prasugrel, 
or ticagrelor in patients with ACS treated with coronary stent implantation who have 
tolerated DAPT without a bleeding complication and who are not at high bleeding risk. In the 
non-ACS setting (SIHD), the guidelines recommend DAPT with clopidogrel for 6 months 
after DES and 1 month after BMS implantation (class I) [30].  
 
Decisions regarding the potency and duration of DAPT require a thoughtful assessment of 
the often-delicate balance between ‘ischemic’ and ‘bleeding’ risks that necessitates 
individualizing of therapy. The latter point has been underscored in recent studies developing 
and validating a clinical prediction tool, the ‘DAPT score’, to provide an accurate tool for the 
assessment of the relative benefit-to-risk profile for L-DAPT vs. S-DAPT. A high DAPT 
score (≥2) predicts ischemic benefit without incremental bleeding risk with L-DAPT [32-33].  
Factors that contribute to a higher DAPT score (favorable for L-DAPT) include diabetes 
mellitus, current cigarette use, prior PCI or prior MI, congestive heart failure or left 
ventricular ejection fraction <30%, MI at presentation, vein graft PCI, and stent diameter <3 
mm. Conversely, older age contributes to a lower (less favorable) DAPT score [29, 32-33] 
 
Additional factors that may need to be considered are stent type/generation, drug availability, 
and patient preference. Newer-generation DES have a lower risk of stent thrombosis and 
appear to require a shorter minimum duration of DAPT [4,6,7,34,35]. In a recent meta-
analysis, rates of ST were found to be higher in patients treated with S-DAPT compared to L-
DAPT after first generation DES implantation but not after second generation DES 
implantation [36]. Suggesting S-DAPT may be optimal in for newer generation stents. 
However, most of the trials were done among primarily low risk, non-ACS patients.  
 
Our meta-analysis has several limitations. First, the current analysis is based on trial-level 
data, which precludes identification of causal association or factors related with recurrent 
ischemia and bleeding events. Second, the trials included in the present study differed in 
terms of design and enrolment criteria. Specifically, there was heterogeneity in terms of 
proportion of stable vs unstable patients and time of randomization. Third, the clinical trials 
included in the current meta-analysis have mostly employed use of clopidogrel. With 
increasing adoption of more potent P2Y12 inhibitors, such as ticagrelor and prasugrel, in 
clinical practice, the relative benefit-to-risk profile of S-DAPT vs L-DAPT remains to be 
established.  Finally, the current analysis is lacking in evaluation of interaction effects of 
stent generation type, novel P2Y12 inhibitors or clinical setting.  
 
In conclusions, in the present analysis of RCTs, S-DAPT was associated lower rates of major 
bleeding but higher rates of MI and a trend towards an increase in ST compared with L-
DAPT. No significant differences were found in rates of all-cause mortality, cardiac 
mortality, TVT and stroke. Our findings indicate that prolonging duration of DAPT requires 
a careful and individualized assessment of the trade-off between ischemic and bleeding 
complications. 
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FIGURES LEGENDS: 
Figure 1 The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
flow chart for the trial selection process 
Figure 2: Forest plot for myocardial infarction with S-DAPT and L-DAPT 
Figure 3. Forest plot for TIMI major bleeding with S-DAPT and L-DAPT 
Figure 4. Forest plot for all cause mortality with S-DAPT and L-DAPT 
Figure 5. Forest plot for cardiac mortality with S-DAPT and L-DAPT 
Figure 6: Forest plot for stent thrombosis with S-DAPT and L-DAPT 
Figure 7. Forest plot for target vessel revascularization with S-DAPT and L-DAPT 
Figure 8. Forest plot for stroke with S-DAPT and L-DAPT 
 
 
 
 
 
Table 1. Clinical outcomes with S-DAPT compared with L-DAPT  
 Odds ratio (95% Confidence interval) 
 
Pinteraction  Hetero-geneity (I2) 
All-cause mortality 0.88 [0.75, 1.04] 0.13 0% 
Cardiac mortality 0.98 [0.79, 1.22] 0.88 0% 
MI 1.40 [1.08, 1.81] 0.01 46% 
ST 1.59 [0.98, 2.60] 0.06 42% 
TVR 0.99 [0.73, 1.34] 0.94 50% 
Stroke 1.01 [0.78, 1.32] 0.91 0% 
TIMI major bleeding 0.60 [0.41, 0.89] 0.01 0% 
MI: myocardial infarction; ST: Stent thrombosis; TIMI: Thrombolysis In Myocardial Infarction; TVR: target vessel 
revascularization 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PRISMA Flowsheet  
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